What We Already Know about This Topic
* A number of response surface models have been developed to describe the relationship between the concentrations of two drugs and their combined clinical effects
What This Article Tells Us That Is New
* When the pharmacodynamic interactions between sevoflurane and remifentanil on various hypnotic and noxious endpoints were characterized by five commonly used interaction models, they were best described by models that assumed no opioid effect when opioid was given alone to patients
* The reduced Greco, scaled C50o hierarchical, and fixed C50o hierarchical models fitted the data reasonably well, but the Minto and Greco models did not
PHARMACODYNAMIC response surface models are three or more dimensional structures that have been developed to quantitatively describe the relationship between two or more drug concentrations with their combined clinical effect. Response surface models are powerful representations of drug interactions, because they combine information about any isobole and the concentration-response curve of any combination of the drugs involved.1
Using the mathematically defined response surface, the corresponding drug effect for any two or more drug concentrations of the interacting drugs can be predicted.1
Various methodological approaches to response surface models are found in the literature. Bol et al.
further developed a previously published response surface model by Greco et al.
to describe the interaction between dexmedetomidine and midazolam in rats.4
The Greco model can be considered as the basic approach to describe quantal response surface models, since it is the original and most simple model for drug interaction. As this model assumes identical slope factors and identical maximal effects for the single concentration effect courses of the interacting drugs, Minto et al.
extended the Greco model to make the response surface modeling more flexible. They defined a variable (originally called θ) as the proportion of one drug in the combination of two potentially interacting drugs.1
More recently, Bouillon et al.
developed a novel mechanistic approach to the interaction between opioids and hypnotics. Using the knowledge that analgesia represents a drug action on ascending neuropathways and that hypnosis is a cortical response that balances the ascending noxious stimulus against drug-induced cortical suppression, they quantified opioid-hypnotic drug interaction in a sequential (also called hierarchical) model.6
As some of the authors of the original paper thought that the initial form of their hierarchical model was overparameterized,2
they designed a less complex form of the model, hereby called the Fixed C50O
which is now applied in one of the commercially available drug interaction displays (Smart Pilot View, Dräger, Lübeck, Germany). In contrast to the Greco and Minto models, the Scaled C50O
and Fixed C50O
Hierarchical models approach comes more close to the clinical pharmacological and physiologic reality.
To characterize the interaction between sevoflurane and remifentanil in blunting responses to verbal (Observer's Assessment of Alertness/Sedation scale) and painful stimuli (pressure algometry, electrical tetanic stimulus, and thermal stimulation), Manyam et al.
constructed a response surface for each pharmacodynamic response using a Logit model approach and found synergy between sevoflurane and remifentanil for all responses.8
As this study suffered from nonsteady-state conditions at the moment of measurements, the authors reevaluated their data using effect-site sevoflurane concentrations and a Greco model instead of a Logit approach.9
Accounting for the lag time between sevoflurane effect-site concentration and end-tidal concentration improved the predictions of responsiveness during anesthesia but had no effect on predicting a response to a noxious stimulus in the recovery room. They concluded that models may be useful in predicting events of clinical interest but large-scale evaluations with numerous patients are needed to better characterize model performance. Also, they did not test if other response surface models would describe the data more accurately.
The aim of this study was to quantify the pharmacodynamic interaction between sevoflurane and remifentanil in patients and to investigate the performance of different interaction models to predict the likelihood of response. Quantal responses to different clinically relevant hypnotic and noxious stimuli were studied.
Materials and Methods
This study used a similar study design as our previously published report.10
After obtaining Institutional Review Board approval (Ghent University Hospital Ethics Committee, Gent, Belgium) and prospective trial registration at ClinicalTrials.gov (NCT00522587), as well as written informed consent, 40 American Society of Anesthesiologists status I or II patients, aged 18 to 60 yr, and scheduled to undergo surgery requiring general anesthesia, were included. Patients were allowed to take their usual medication. Exclusion criteria were weight less than 70% or more than 130% of ideal body weight, neurologic disorder, diseases involving the cardiovascular system (hypertension, coronary artery disease, prior acute myocardial infarction, any valvular and/or myocardial disease involving decrease in ejection fraction, arrhythmias, which are either symptomatic or require continuous medication/pacemaker/automatic internal cardioverter defibrillator), pulmonary diseases, gastric diseases, endocrinologic diseases, and recent use of psycho-active medication or more than 20 g of alcohol daily. The complete study was executed in a quiet operation room before the start of the surgical procedure.
This study was performed as a randomized, prospective, open-label study. After the unpremedicated patients arrived in the operating room, standard monitors (electrocardiogram, noninvasive blood pressure, SpO2), M-entropy using a Datex S/5 Anesthesia Monitor (GE Healthcare, Helsinki, Finland) and bispectral index using a Aspect A-2000 monitor (Covidien, Norwood, MA) were connected, and a large forearm vein was cannulated. Thereafter, the patients were preoxygenated with 6 l/min O2 at a FI = 1.0 for 5 min, using a tight-fitting facemask, which also served to sample exhaled air for end-tidal carbon dioxide measurement. All medical devices are approved for the purposes applied in the study. All drugs and the way of administration, either alone or in combination, are approved for clinical use under the studied conditions. No “off label” drug applications were used (European situation). Vital signs as well as end-tidal sevoflurane concentrations, respiratory data (tidal volume, minute volume, end-tidal carbon dioxide), and infusion related data (predicted concentrations, amounts infused) were continuously recorded on a computer hard disk using RUGLOOP II data recording software (Demed, Temse, Belgium).
Remifentanil was administered by using a target-controlled infusion technique based on a three-compartment model and an effect-site compartment as published by Minto et al.11
Remifentanil infusion was administered by using an Alaris Asena pump (Carefusion, Basingstoke, United Kingdom). RUGLOOP II TCI driver (Demed) controlled the pump at infusion rates between 0 and 1,200 ml/h via
an RS-232 interface. Sevoflurane was administered in 50% O2
and 50% air by using a standard out of circle vaporizer and a standard breathing circuit of an ADU anesthesia workstation (Datex/Ohmeda, GE Healthcare). In all steps, the sevoflurane vaporizer was set to maximum until 80% of the target concentration was reached, then it was turned down to the target setting. A fresh gas flow above minute ventilation was used throughout the study.
The study design was a modification of the criss-cross design proposed by Short et al.3
The choice of the sevoflurane/remifentanil concentrations pairs were based on the sevoflurane Ce50 (Ce50sevo
) to suppress the response to skin incision (= minimal anesthetic concentration, MAC) of 1.85%13
and a remifentanil Ce50 (= remifentanil concentration reducing the MACSEVO
by 50%) of 1.5 ng/ml14
Equation (Uncited)Image Tools
where opioid effect is the relative effect of remifentanil on Ce50SEVO, CeREMI is the effect-site concentration of remifentanil, CeSEVO is the effect-site concentration of sevoflurane, and CeSEVO(norm) is the effect-site concentration of sevoflurane normalized to MAC, taking into account the opioid effect.
Table 1-a. Concentra...Image Tools
We randomized 40 patients to receive specific combinations of sevoflurane and remifentanil as simulated and described in the next paragraph. Before induction the subjects were randomly assigned to receive four prespecified pairs of sevoflurane and remifentanil concentrations. In half of the patients, remifentanil was held constant, and sevoflurane was stepwise increased; in the other half, sevoflurane was held constant and remifentanil was stepwise increased (table 1
). For each of the 10 escalating combinations, three patients were included. To study the boundaries of the response surface (single drug without interaction), five patients were given sevoflurane only (0.7 to 3.5 vol.%) and five were given remifentanil (2–12 ng/ml) during the study period. The maximum CeSEVO
was set at 3.5 vol.%, and maximum CeREMI
was set at 12 ng/ml. A maximum of four steps was used to explore a single slice of the response surface. No other drugs were given, except for a possible 0.1 mg bolus of phenylephrine if mean arterial blood pressure dropped below 50 mmHg.
Assessment of Clinical Response
Table 1-b. Concentra...Image Tools
For each concentration step, the clinical response was assessed 12 min after reaching the target concentrations to allow for plasma effect-site equilibration. The patient was exposed to the following series of stimuli with increasing intensity: (1) verbal and nonpainful tactile stimuli according to the Observer's Assessment of Alertness/Sedation (OAA/S score)15
(an OAA/S score less than 2 was considered as tolerant); (2) a tetanic stimulus of the ulnar nerve for 5 s by using the standard neurostimulator used in the clinical setting to test the level of muscle relaxation (100 Hz, 60 mA, Tristim NS3A peripheral nerve stimulator; Life Tech, Houston, TX); (3) insertion of a laryngeal mask airway (LMA size 3 for women and 4 for men, LMA Unique®, The Surgical Company, Amersfoort, The Netherlands); (4) laryngoscopy aiming at full visualization of the vocal chords by using a size-3 curved Macintosh-type blade (HEINE Optotechnik GmbH & Co KG, Herrsching, Germany). Verbal response, eye opening, grimacing, coughing, withdrawal, or any other purposeful or nonpurposeful movement, including jaw clenching and bucking after a stimulus, were defined as a response. Absence of a response implied tolerance of the stimulus and was labeled 0, and presence of a response implied no tolerance of the stimulus and was labeled 1 in the case report form. All assessments were performed by one investigator to minimize interobserver variability. If there was no response to the first stimulus, the next stimulus was applied 1 min after the response assessment of the first. The assessment at each drug concentration level was stopped as soon as a response was observed or the patient tolerated laryngoscopy. If there was no response to laryngoscopy at the highest predefined drug combination, data acquisition was stopped, and the patient's trachea was intubated after the administration of 0.9 mg/kg rocuronium.
Pharmacodynamic Analysis of Quantal Responses
The four quantal responses, defined as tolerance to shaking and shouting, tolerance to a 5 s tetanic stimulus, tolerance to LMA insertion, and tolerance to laryngoscopy were modeled using five interaction models: Greco model,4
Reduced Greco model,2
and Fixed C50O
Details of the models can be found in the appendix.
An OAA/S score of 0–1 was considered as tolerant to shaking and shouting, and a score of 2–5 as responsive.
For remifentanil, the targeted effect-site concentration after 12 min of equilibration was considered as the steady-state concentration taking into account the reported11
age-dependent equilibration half-time of 0.94, 1.32, and 2.20 min for 20, 50, and 80 yr, respectively, and was used as the remifentanil effect-site concentration (CeREMI
) in the analysis. For sevoflurane, the alveolar concentration measured by the S5 Anesthesia Monitor (GE Healthcare) via
end-expiratory measurement after 12 min of equilibration was considered as the steady state concentration, and was used as sevoflurane effect-site concentration (CeSEVO
) in the analysis. To reduce data noise in CeREMI
, the median value of 11 measurements at 5 s intervals during 1 min preceding the assessment of the OAA/S score were used. The duration of equilibration of 12 min was five times the reported equilibration half-life for sevoflurane of 2.4 min.17
In the current data set it was observed in several cases that the patient was tolerant to a stimulus, whereas the same patient was responsive to the preceding, a priori
considered less intense stimulus. Therefore the approach described by Bouillon et al.6
and by Schumacher et al.
combining the observed responses to the four stimuli into a single value, could not be applied. Instead the observed response to each stimulus was compared to the probability of that response according to the model, irrespective of the response to the other stimuli.
The model parameters were estimated using NONMEM VI version 2.0 (Icon Development Solutions, Ellicott City, MD), using FOCE LAPLACE and LIKELIHOOD options.
Platform was Windows XP (Microsoft, Redmond, WA) and compiler was G95. For all parameters interindividual variability was either assumed to be absent, or to have a log-normal distribution. A single value for the individual deviation from the typical value (η in NONMEM) was used for Ce50 of sevoflurane and remifentanil for all stimuli, in accordance with the assumption that this value reflects the sensitivity of that individual for hypnotic and opioid drugs.
Model building was performed starting with the simplest form of each model, and expanding the model with interaction terms and interindividual variability until the decrease of the objective function value (OFV) was not statistically significant using the chi-square test. The best fitting model was selected using Akaike Information Criterion, calculated as OFV + 2p, where p is the number of parameters in the model. The NONMEM analysis was performed with various values for initial estimates and boundary values. The results were accepted as valid only if both minimization and covariance step were successful, unless stated otherwise.
To evaluate the final model a bootstrap analysis was performed, based on 1,000 sets of 40 patients each, randomly selected from the available 40 patients, using a custom program written in C. Results were analyzed in Excel (Microsoft). In addition, log-likelihood profiles were calculated for each population parameter, and the 95% CIs were obtained from these data assuming a chi-square distribution with one degree of freedom and P = 0.025, resulting in a critical difference of 5.02 in the OFV.
Several performance measures were calculated from the prediction errors, i.e., the difference between the predicted probability of tolerance minus the observed response (0 for responsive, 1 for tolerant): mean prediction error, mean absolute prediction error, and root mean squared error. In addition, the prediction error score was calculated as the percentage of mispredicted responses, i.e., if tolerant, P < 0.5, or if responsive, P > 0.5.
All model parameters are reported as typical values with relative standard errors in % within parentheses, and clinical data are given as mean and SD or as median and range, when appropriate.
In total, 40 patients (26 females, 14 males) were included in this study. The demographics are as follows: body weight: 66 ± 11 kg, height: 172 ± 8 cm, age: 30 ± 11 yr. All patients were classified as American Society of Anesthesiologists status I.
In total, the data sets contained 159 periods of testing (40 patients with 4 periods per patient, minus 1 missing period where no stimulus was given). According to the protocol escalating stimulus intensity was assumed in the order of shaking and shouting, tetanic stimulation, LMA insertion, and laryngoscopy. In 74 cases a stimulus was not applied for ethical reasons, because the patient was responsive to the preceding less intense stimulus at the same concentrations of sevoflurane and remifentanil. The patient was then considered a responder to more intense stimuli for data analysis. In 14 other cases a stimulus was not given for other reasons (such as severe hemodynamic changes), although the patient was tolerant to the preceding stimulus. In the data analysis these data were treated as missing values.
The Greco model did not result in plausible parameter estimates; both Ce50REMI and α became very large, whereas the OFV was higher than for the Reduced Greco model (data not shown). If the parameters were allowed to take very large values, the OFV approached that of the Reduced Greco model, and the ratio Ce50REMI/α approached Ce50REMI of the Reduced Greco model. Therefore the original Greco model was not further considered. The Akaike Information Criterion of the Minto model was markedly higher than for the other models, and the estimated Ce50REMI was above the highest remifentanil concentration applied. Compared with the other models, the Akaike Information Criterion of the Fixed C50O Hierarchical model was the lowest, indicating the best-fitting model.
Allowing variation of the Ce50REMI
and the slope parameters among the different stimuli in the modeling process did not significantly reduce the OFV. Even estimating a different Ce50REMI
for the nonnoxious shaking and shouting compared with the Ce50REMI
for tetanic stimulation, LMA insertion, and laryngoscopy did not result in a significant improvement of the OFV. In the final model a common Ce50REMI
and common slope parameters for all stimuli were obtained, whereas the Ce50SEVO
was stimulus specific (table 2
Inclusion of interindividual variability in each parameter was tested either alone or in combinations. In all cases interindividual variability was the same for each stimulus. The results have been summarized in table 2
. For all models, inclusion of interindividual variability in Ce50SEVO
significantly improved the OFV (P < 0.01); but not interindividual variability of other parameters. We performed a covariate analysis on patient weight, height, age, gender, and order of administration of remifentanil and sevoflurane. None of these covariates did improve the fit significantly.
The Reduced Greco model is identical with the Fixed C50O Hierarchical model if γO is fixed to 1, and therefore both models may be compared using the likelihood ratio. Given the reduction of 8.5 in OFV it can be concluded that the Fixed C50O Hierarchical model fits significantly better to the data than the Reduced Greco model. The Scaled C50O and Fixed C50O Hierarchical models cannot be compared using the likelihood ratio, because both models have the same number of parameters. However, the reduction of 4.1 in the OFV indicates that the Fixed C50O Hierarchical model fits better to the data.
The differences between the four models with respect to the performance measures were rather small (table 2
The results of the final model, i.e.
, Fixed C50O
Hierarchical model with interindividual variability in Ce50SEVO
, were checked by performing a bootstrap analysis, based on 1,000 sets; 994 sets resulted in a successful minimization, and 983 sets gave a successful covariance step. The results of the bootstrap analysis were in good agreement with the NONMEM results (table 3
). Also, the CIs estimated from the bootstrap analysis and from the log-likelihood profiles were comparable (table 3
). The log-likelihood profiles for the parameters of the Fixed C50O
Hierarchical model are depicted in figure 1
Response Surface and Isoboles
The response surfaces for the probabilities of tolerance to each stimulus are shown in figure 2
. Figure 3
compares the isoboles for 50% probability of tolerance to the four stimuli for the four models. Figure 4
shows the isoboles for 50% probability of tolerance to the four stimuli for the Fixed C50O
Hierarchical model and the observed responses. Figure 5
compares the isoboles for 50% probability of tolerance to the four stimuli for the four models. In figure 6
, the isoboles for 5%, 50%, and 95% probability of tolerance to the four stimuli for the Fixed C50O
Hierarchical model are shown. Figure 7
shows the isoboles for 95% probability of tolerance to laryngoscopy for the four models, illustrating the clinical significant difference between the Minto model and the three other models.
As expected, the pharmacodynamic interaction between sevoflurane and remifentanil was strongly synergistic for both the hypnotic and the analgesic components of anesthesia, as illustrated by tolerance to shake and shout, tetanic stimulation, LMA insertion, and laryngoscopy.2
The main finding of this study is the validity of the Fixed C50O
assuming an identical Ce50 and slope parameter for the opioid and an identical slope parameter of the hypnotic for different stimuli, but keeping different Ce50hypnotic
for different stimuli. The model is thus validated not only for the propofol-remifentanil but also for the sevoflurane-remifentanil combination. The flexibility of the Fixed C50O
Hierarchical model where only the Ce50opioid
, the Ce50hypnotic
and slope parameters for the opioid and hypnotic are needed as input parameters, is of importance for the parsimonious description of the interaction and therefore very useful in the context of anesthesia drug displays.
The Minto model with a Ce50REMI of 14.3 ng/ml was statistically inferior, whereas the original Greco model did not even support a reliable estimation of the Ce50REMI (estimated values above 50 ng/ml). This is in agreement with the clinical experience that in the absence of a hypnotic drug opioids do not suppress the response to stimulation, at least at clinically reasonable opioid concentrations. The Hierarchical models are semimechanistic models that have been developed to detect synergism for the combination of an analgesic and a hypnotic drug using a simple reconstruction of neuropathic pathways, as opposed to other more generalistic models. These Hierarchical models, as well as the Reduced Greco model, assume no relevant opioid effect if given alone, and therefore these models fitted better to the data than the Greco and Minto models. The differences between the Reduced Greco model, Scaled C50O Hierarchical model, and Fixed C50O Hierarchical model were rather small, and each of these three models fitted reasonably well to the data. However, the OFV and Akaike Information Criterion unequivocally showed that the Fixed C50O Hierarchical model fit best to our data.
The conclusions with respect to the best fitting model should not be translated to interactions of different classes of drugs. Each of these models is an empirical model that needs to be validated for each application. The Reduced Greco and both Hierarchical models are applicable when one of the drugs does not exert an effect when given alone, as is the case for the sevoflurane-remifentanil combination studied in this investigation. For other drug combinations where both drugs can exert a full effect, the original Greco model and the Minto model may be appropriate. For combinations where one of the drugs can only exert a partial effect, a modified version of the Minto model seems appropriate.
To evaluate the clinical relevance of the observed differences between the models, the isoboles for 95% probability of tolerance to laryngoscopy for the four models are shown in figure 7
. At a fixed remifentanil concentration of 3 ng/ml, the sevoflurane concentration predicted by the Minto, Reduced Greco, Scaled C50O
Hierarchical, and Fixed C50O
Hierarchical model is 1.59, 1.27, 1.08, and 1.19 vol.%, respectively. This illustrates the deviating characteristics of the Minto model, and the relatively small differences between the Reduced Greco and both Hierarchical models. Clinicians aim at titrating their drugs during anesthesia at least at a level of 95% probability of tolerance, so at a specific remifentanil concentration, applying the Minto model would result in the use of a clinically relevant higher sevoflurane concentration than when using the other models.
Response surfaces or interaction isoboles are used in anesthetic drug displays as reference to interpret the current effect-site concentrations estimated in the patient. The parameter estimates of the model are therefore crucial. According to the Fixed C50O
Hierarchical model, the Ce50s of the hypnotic are used to rank different stimuli according to their intensity. The Ce50SEVO
for tolerance of shaking and shouting (nonnoxious) and tetanic stimulation (noxious) were similar. The Ce50SEVO
for tolerance of LMA insertion and for laryngoscopy were also similar but substantially higher. In the previous study on the interaction of sevoflurane and propofol performed with the same stimuli by the same investigators,10
the Ce50 values for sevoflurane for tolerance to shake and shout, tetanic stimulation, LMA insertion, and laryngoscopy were 1.03, 2.11, 2.55, and 2.83 vol.% respectively, which is markedly different from that found in the present study (1.47, 1.48, 2.09, and 2.00 vol.%, respectively). Furthermore, the slope reported by Schumacher et al.
was 17.6, whereas in the present study it was 7.41. To elucidate the cause of these differences, the data points of the previous and the current study where sevoflurane was given alone were reanalyzed (table 4
). The parameter estimates obtained from the “sevoflurane alone” data of the two studies still differ, although the difference is smaller and the order of the Ce50s was similar in both studies. We can only speculate why the Ce50SEVO
for tolerance to shake and shout was lower and the Ce50SEVO
for tolerance to laryngoscopy was higher in the previous compared to the current study. Age, weight, and height were similar in the two studies. Classification of the subjects in responders and nonresponders was similar (a response was assumed if there was an observed response to a given stimulus, and if there was a response to a lower intensity stimulus and when the subsequent higher intensity stimulus was not applied). The pattern and current intensity of the electrical stimulus was also the same. The individual airway anatomy of the patients may affect the force to be applied during LMA insertion and the pressure applied with the laryngoscope to visualize the vocal cords. This may explain in part the difference between the Ce50s for tolerance to LMA insertion and laryngoscopy but not the difference between Ce50s for tolerance to shake and shout and tetanic stimulation.
A synergistic interaction between sevoflurane and remifentanil for both the hypnotic and analgesic stimuli using surface modeling was also found previously.8
However, their parameter estimates differ markedly from those of the current study. Several reasons may explain this discrepancy: Whereas Manyam et al.
used a logistic regression model, Johnson used the Greco model in his reanalysis of the same data. In the study of Manyam et al.
the stimuli were given 5 min after achieving a stable end-tidal sevoflurane concentration, whereas in our study the equilibration was allowed for 12 min, which is five times the reported equilibration half-life for sevoflurane of 2.4 min.17
To compensate for this disequilibrium, Johnson et al.9
used an estimated effect-site concentration to describe the hysteresis with the end-tidal concentration. The Ce50REMI
for OAA/S≤1 during emergence (no return of consciousness) reported by Johnson et al.
was 50.9 ng/ml, which is far above the investigated concentration range applied and may thus not be reliable, although it reflects the weak hypnotic potency of opioids. The Ce50REMI
for tolerance of tibial pressure was 1.3 ng/ml, which is in the range of the common Ce50REMI
in the current study as well as in the previous studies.2
In our study the Ce50REMI
estimated with the Reduced Greco model was 2.28 ng/ml for OAAS≤1 (table 2
), which is lower than the value calculated from the ratio Ce50/α reported by Johnson et al.
(50.9/9.4 = 5.4 ng/ml).
Whereas Johnson et al. reported a different slope for OAAS≤1 (5.2) and tolerance of tibial pressure (2.7), we did not find a significant difference between the slopes for the different stimuli, and in our final model the common slope was 7.4. It seems that the data from Manyam, reanalyzed by Johnson and our data are difficult to compare because of the different methodology and the different endpoints used.
Our data are in line with the previous data on MAC reduction for various inhaled anesthetics in the presence of opioids.13
Whereas studies using multiple stimuli and several combinations of a hypnotic and an opioid in a criss-cross design6
only one stimulus (skin incision) at one randomly assigned combination of the two drugs in one patient was applied in the traditional MAC depression studies. The advantage of the former is a reduction of the number of subjects while maintaining a sufficient number of data points for parameter estimation.
Current interaction displays use two different stimuli and the related interaction models as reference to quantify the anesthetic potency of a given combination of a hypnotic (propofol or volatile) and an opioid. The Fixed C50O Hierarchical model appears to be the most appropriate to define the reference lines or numbers to guide the clinician in rational dosing. The two stimuli used in interaction displays as reference must be clearly different in intensity, i.e., significantly differ in their Ce50hypnotic. According to the present and previous data, “shaking and shouting” and “laryngoscopy” with their clearly distinct Ce50s, are therefore reasonable reference stimuli representing a superficial (near loss of consciousness) and a deeper state of anesthesia needed for surgery.
In conclusion, we confirmed that the pharmacodynamic interaction between sevoflurane and remifentanil was strongly synergistic for both the hypnotic and the analgesic components of anesthesia. We illustrated the importance of exploring the various surface modeling approaches when studying pharmacodynamic drug interactions as model selection might influence the results. In this particular investigation, the Fixed C50O Hierarchical model best fits our data on sevoflurane remifentanil interaction and it appears to be an appropriate model for use in hypnotic-opioid drug interaction displays. However, the prediction performance was not essentially different between the Reduced Greco, Scaled C50O Hierarchical, and Fixed C50O Hierarchical models.
Appendix: Binary Response Models
The probability of tolerance, P, to a certain stimulus can be expressed as
where U represents the normalized combined potency of one or more drugs and is a function of the drug effect-site concentrations and model parameters, reflecting the relative drug concentration, and γ is the slope parameter reflecting the steepness of the concentration-effect relationship. Different interaction models differ with respect to the functional form of U and γ, as described below.
is the general form of all binary response models described below, and is used in earlier publications, either explicitly or implicitly, in some cases using different symbols for U and γ (e.g.
, in Luginbuhl,7
N and φ, respectively).
We focus here on models describing the interaction of an opioid (O) and a hypnotic (H) on the probability of tolerance. For each drug we normalize the effect-site concentrations to the related C50, using
Equation (Uncited)Image Tools
where UO and UH are the normalized opioid and hypnotic effect-site concentrations, CO is the effect-site concentration of the opioid, CH is the effect-site concentration of the hypnotic, C50O is the effect-site concentration of the opioid that results in P = 0.5 in the absence of the hypnotic, and C50H is the effect-site concentration of the hypnotic that results in P = 0.5 in the absence of opioid.
In the case of multiple stimuli, the parameters for each stimulus may be different. Usually, however, one or more parameters are chosen identical for each stimulus, to allow reliable estimation of parameters from a limited number of observations.
The Greco model is a simplification of the original Greco model, and is an extrapolation from the 50% effect isobole2
where U is the total potency, α is a dimensionless interaction parameter (α = 0: additive; α < 0 infraadditive; α > 0: supraadditive), and UH and UO are the normalized concentrations of the hypnotic and opioid respectively.
The model has four parameters: C50O, C50H, γ, and α. In the case of multiple (N) stimuli, there are 4.N model parameters; assuming equal values for γ and α for each stimulus, there are 2.N + 2 parameters (C50O and C50H for each additional stimulus). The model can be further reduced by assuming a common value for C50O for each stimulus; in this case there are N + 3 parameters (one additional parameter for each stimulus).
Reduced Greco Model without Effect of the Opioid Alone
In the case of the interaction of opioids with hypnotics, the effect of the opioid alone on P
may be too small to accurately assess the C50O
(i.e., the actual value of C50O
is very high). The Greco model can then be easily modified by leaving out the term UO
from Eq. A4
Equation (Uncited)Image Tools
which may be written after rearrangement and replacement of UO
according to Eq. A2
The parameters C50O
and α cannot be estimated independently, since only their ratio α/C50O
appears in Eq. A6
. Therefore Bouillon2
replaced the term α/C50O
by a single parameter α′, resulting in A7
Alternatively, α may be fixed to 1, resulting in A8, which is equal to A9
Equation (Uncited)Image Tools
C50O may now be interpreted as the concentration of the opioid that decreases C50H by 50%: If CO = C50O (UO = 1), U = 2×UH, i.e., the concentration of the hypnotic required to achieve a certain potency U, and thus a certain probability of tolerance P, is reduced by a factor 2, compared to the concentration in the absence of the opioid.
Both methods are equivalent and produce identical results. Fixing the term α to 1 instead of introducing another term α' has the advantage that the observed value of C50O can be directly interpreted as the concentration that decreases C50H by 50%, whereas the meaning of the term α′ in the Bouillon method is more difficult to explain.
There are three model parameters to be estimated in the Reduced Greco model: C50H, γ, and α′ in the Bouillon method, and C50O, C50H, and γ in the second method. In the case of multiple (N) stimuli, there are 3.N model parameters; assuming an equal value for γ for each stimulus, there are 2.N + 1 parameters. The model can be further reduced by assuming a common value for C50O for each stimulus; in this case there are N + 2 parameters.
The Minto model1
may be described by the following equations, A10
where θ is the fraction of the potency of one drug (in this case the hypnotic) to the total potency of both drugs (not to be confounded with the term θ in NONMEM). The value of θ is between 0 and 1 according to the relative contribution of the two drugs to the total potency UH
. Equation A11
is the potency of two drugs in the combination θ yielding half maximal effect, and βU50
is a dimensionless interaction coefficient relating θ (fraction of hypnotic) and 1-θ (fraction of opioid) to U50
(higher-order functions of θ may be used to accommodate more complex shapes of interaction). Equation A12
where U is the potency of the two drugs normalized to U50.
The steepness parameter γ is a model parameter, or a function of the ratio of the drug concentrations (θ) and model parameters (C50O
), and may be written as a linear interpolation between γH
, and γO
, and an interaction term analogous to Eq. A11
(higher-order functions of θ may be used to accommodate more complex shapes of interaction): A13
Note that Eqs. A11
have been rearranged from the corresponding equations in the original paper of the Minto model,1
to clarify the interaction.
There are four model parameters: C50O
, γ, and βU50
, or six model parameters: C50O
, and βγ
. In the case of multiple (N) stimuli, there are 4.N (or 6.N) model parameters; assuming an equal value for γ's and β's for each stimulus, there are 2.N + 2 (or 2.N + 4) parameters. The model can be further reduced by assuming a common value for C50O
for each stimulus; in this case there are N + 3 (or N + 5) parameters. In the current implementation using Eq. A1
the Minto model implies that both drugs on their own may yield the maximal effect.
The original Hierarchical model6
may be written as A14,
where postopioid_intensity is the stimulus intensity after attenuation by the opioid, and preopioid_intensity is the intensity of the stimulus in the absence of opioid.
corresponds to the general Eq. A1
may be combined to eliminate the term postopioid_intensity with A17,
The original Hierarchical model6
was considered overparameterized.2
The parameters preopioid_intensity, C50H
, and C50O
cannot be estimated uniquely, since the values of C50H
, and C50O
can always be adjusted to offset any value of preopioid_intensity.
In the case of a single stimulus, the overparametrization can be solved by fixing preopioid_intensity to 1, reducing Eq. A17
demonstrates that, for single stimulus, the Hierarchical model is a simple extension of the Reduced Greco model, i.e.
, by adding an exponent γO
in Eq. A9
, yielding Eq. A18
In the case of multiple stimuli, the overparametrization can be solved in various ways, leading to different models: the Scaled C50O and the Fixed C50O Hierarchical model.
Scaled C50O Hierarchical Model
This approach is consistent with the concept described by Bouillon et al.
where the C50o
is multiplied by preopioid intensity to reflect the decreasing potency of opioids in attenuating pain as the intensity of the pain increases.
The Scaled C50O Hierarchical model constrains C50Oi and C50Hi for i > 1 to:
C50Oi = C50O1 * preopioid_intensityi
C50Hi = C50H1 * preopioid_intensityi
In short, the characteristic feature of the Scaled C50O Hierarchical model is that the stimulus intensity is a factor by which the C50s of both drugs are multiplied.
There are four model parameters: C50O, C50H, γ, and γO. In the case of multiple (N) stimuli, there are 4.N model parameters; the constraints on C50Oi and C50Hi reduce the number of free parameters to 3.N + 1; assuming that γ and γO are not affected by the type and intensity of the stimulus, there are N + 3 parameters (C50O1, γ, γO, and N values of C50Hi; values of C50Oi for i more than 1 follow from the constraints).
Fixed C50O Hierarchical Model
The modified Hierarchical model proposed by Bouillon2
introduced a different constraint on C50Oi
that is also reasonable and testable: C50O
is the same for all stimuli. Therefore this model is referred to as 'Fixed C50O
Hierarchical model', constraining C50Oi
for i > 1 to:
C50Oi = C50O1
C50Hi = C50H1 * preopioid_intensityi
This constraint is identical to omitting preopioid_intensity from the denominator of Eq. A15
. From these constraints and Eq. A18
it follows that the Fixed C50O
Hierarchical model is an extension of the Reduced Greco model, i.e.
, by adding an exponent γO
in Eq. A9
and with a common parameter C50O
for all stimuli. Note that in the Fixed C50O
Hierarchical model proposed by Bouillon2
was assumed to be 1 (equation on page 481 of that paper), making the model identical to the Reduced Greco model.
The number of model parameter is identical to that of the Scaled C50O Hierarchical model (C50O, γ, γO, and N values for C50Hi).
Relationships between Models
The characteristics and relationships between the models can be summarized as follows:
The Greco model and the Minto model as commonly implemented assume an effect of the opioid given alone, whereas the other models assume that the opioid alone has no effect on the response to a stimulus;
The Reduced Greco model is a reduction of the Greco model; the models are identical if the parameters C50O and α of the Greco model are infinitely large, and their ratio C50O/α) is equal to C50O of the Reduced Greco model;
The Reduced Greco model with a common parameter C50O for all stimuli and the Fixed C50O Hierarchical model are identical if the parameter γO is fixed to 1;
The Scaled C50O Hierarchical model assumes that the C50 of opioid (C50O) and hypnotic (C50H) are multiplied by a common factor representing the intensity of the stimulus, i.e., the ratio C50O/C50H are the same for each stimulus;
The Fixed C50O Hierarchical model assumes a common C50O for each stimulus;
For a single stimulus the Fixed C50O Hierarchical model is identical to the Scaled C50O Hierarchical model.
1. Minto CF, Schnider TW, Short TG, Gregg KM, Gentilini A, Shafer SL: Response surface model for anesthetic drug interactions. ANESTHESIOLOGY 2000; 92:1603–16
2. Bouillon TW: Hypnotic and Opioid Anesthetic Drug Interactions on the CNS, Focus on Response Surface Modelling, Modern Anesthetics, Handbook of Experimental Pharmacology 182. Berlin: Heidelberg, Springer-Verlag; 2008
3. Short TG, Ho TY, Minto CF, Schnider TW, Shafer SL: Efficient trial design for eliciting a pharmacokinetic-pharmacodynamic model-based response surface describing the interaction between two intravenous anesthetic drugs. ANESTHESIOLOGY 2002; 96:400–8
4. Greco WR, Park HS, Rustum YM: Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1990; 50:5318–27
5. Bol CJ, Vogelaar JP, Tang JP, Mandema JW: Quantification of pharmacodynamic interactions between dexmedetomidine and midazolam in the rat. J Pharmacol Exp Ther 2000; 294:347–55
6. Bouillon TW, Bruhn J, Radulescu L, Andresen C, Shafer TJ, Cohane C, Shafer SL: Pharmacodynamic interaction between propofol and remifentanil regarding hypnosis, tolerance of laryngoscopy, bispectral index, and electroencephalographic approximate entropy. ANESTHESIOLOGY 2004; 100:1353–72
7. Luginbühl M, Schumacher PM, Vuilleumier P, Vereecke H, Heyse B, Bouillon TW, Struys MM: Noxious stimulation response index: A novel anesthetic state index based on hypnotic-opioid interaction. ANESTHESIOLOGY 2010; 112:872–80
8. Manyam SC, Gupta DK, Johnson KB, White JL, Pace NL, Westenskow DR, Egan TD: Opioid-volatile anesthetic synergy: A response surface model with remifentanil and sevoflurane as prototypes. ANESTHESIOLOGY 2006; 105:267–78
9. Johnson KB, Syroid ND, Gupta DK, Manyam SC, Pace NL, LaPierre CD, Egan TD, White JL, Tyler D, Westenskow DR: An evaluation of remifentanil-sevoflurane response surface models in patients emerging from anesthesia: Model improvement using effect-site sevoflurane concentrations. Anesth Analg 2010; 111:387–94
10. Schumacher PM, Dossche J, Mortier EP, Luginbuehl M, Bouillon TW, Struys MM: Response surface modeling of the interaction between propofol and sevoflurane. ANESTHESIOLOGY 2009; 111:790–804
11. Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Gambus PL, Billard V, Hoke JF, Moore KH, Hermann DJ, Muir KT, Mandema JW, Shafer SL: Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I Model development. ANESTHESIOLOGY 1997; 86:10–23
12. Minto CF, Schnider TW, Shafer SL: Pharmacokinetics and pharmacodynamics of remifentanil. II Model application. ANESTHESIOLOGY 1997; 86:24–33
13. Lang E, Kapila A, Shlugman D, Hoke JF, Sebel PS, Glass PS: Reduction of isoflurane minimal alveolar concentration by remifentanil. ANESTHESIOLOGY 1996; 85:721–8
14. Katoh T, Kobayashi S, Suzuki A, Iwamoto T, Bito H, Ikeda K: The effect of fentanyl on sevoflurane requirements for somatic and sympathetic responses to surgical incision. ANESTHESIOLOGY 1999; 90:398–405
15. Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, Schwam EM, Siegel JL: Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: Study with intravenous midazolam. J Clin Psychopharmacol 1990; 10:244–51
16. Mertens MJ, Olofsen E, Engbers FH, Burm AG, Bovill JG, Vuyk J: Propofol reduces perioperative remifentanil requirements in a synergistic manner: Response surface modeling of perioperative remifentanil-propofol interactions. ANESTHESIOLOGY 2003; 99:347–59
17. Rehberg B, Bouillon T, Zinserling J, Hoeft A: Comparative pharmacodynamic modeling of the electroencephalography-slowing effect of isoflurane, sevoflurane, and desflurane. ANESTHESIOLOGY 1999; 91:397–405
18. McEwan AI, Smith C, Dyar O, Goodman D, Smith LR, Glass PS: Isoflurane minimum alveolar concentration reduction by fentanyl. ANESTHESIOLOGY 1993; 78:864–9
19. Brunner MD, Braithwaite P, Jhaveri R, McEwan AI, Goodman DK, Smith LR, Glass PS: MAC reduction of isoflurane by sufentanil. Br J Anaesth 1994; 72:42–6
20. Westmoreland CL, Sebel PS, Gropper A: Fentanyl or alfentanil decreases the minimum alveolar anesthetic concentration of isoflurane in surgical patients. Anesth Analg 1994; 78:23–8
21. Katoh T, Ikeda K: The effects of fentanyl on sevoflurane requirements for loss of consciousness and skin incision. ANESTHESIOLOGY 1998; 88:18–24
© 2012 American Society of Anesthesiologists, Inc.